| __timestamp | CymaBay Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 5078000000 |
| Thursday, January 1, 2015 | 8871000 | 4717000000 |
| Friday, January 1, 2016 | 9645000 | 5096000000 |
| Sunday, January 1, 2017 | 12387000 | 4986000000 |
| Monday, January 1, 2018 | 14381000 | 4214000000 |
| Tuesday, January 1, 2019 | 19238000 | 3806000000 |
| Wednesday, January 1, 2020 | 17425000 | 3671000000 |
| Friday, January 1, 2021 | 23040000 | 3528000000 |
| Saturday, January 1, 2022 | 25116000 | 3445000000 |
| Sunday, January 1, 2023 | 51953000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and CymaBay Therapeutics, Inc. from 2014 to 2023.
Teva, a global leader, consistently reported SG&A expenses in the billions, peaking at approximately $5 billion in 2016. However, a downward trend is evident, with a 32% decrease by 2023. In contrast, CymaBay, a smaller player, showed a remarkable 535% increase in SG&A expenses over the same period, reflecting its aggressive growth strategy.
This divergence highlights Teva's cost-cutting measures amidst market challenges, while CymaBay's rising expenses suggest expansion efforts. Investors and analysts should consider these trends when evaluating the strategic directions of these companies.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Genmab A/S
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Ascendis Pharma A/S
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Catalent, Inc. and CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights